Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Chief Business Officer | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | Direct | 240,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 240,000 · Balance 240,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 21:22 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 240,000 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001951238-26-000003 · form4-01052026_090113.xml · derivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 23:42 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001951238-25-000005 · form4-11142025_111150.xml · derivative · entry 4 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,047 Underlying: Common Stock · 30,000 shares Expires 2029-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 23:42 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 136,380 | $8.86 | $1,208,790.49 |
DisclosureSEC source: 0001951238-25-000005 · form4-11142025_111150.xml · nonDerivative · entry 3 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 23:42 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 30,000 | $8.91 | $267,357.00 |
DisclosureSEC source: 0001951238-25-000005 · form4-11142025_111150.xml · nonDerivative · entry 2 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F1 · price: The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 23:42 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 30,000 | $0.84 | $25,200.00 |
DisclosureSEC source: 0001951238-25-000005 · form4-11142025_111150.xml · nonDerivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 274,100 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001415889-25-000461 · form4-01032025_040126.xml · derivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,100 Underlying: Common Stock · 274,100 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025. Read SEC document |
| December 13, 2024 Filed Dec 14, 2024 00:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,272 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001415889-24-029377 · form4-12142024_121217.xml · derivative · entry 6 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,461 Underlying: Common Stock · 27,272 shares Expires 2031-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 13, 2024 Filed Dec 14, 2024 00:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 27,272 | $12.06 | $328,968.50 |
DisclosureSEC source: 0001415889-24-029377 · form4-12142024_121217.xml · nonDerivative · entry 4 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F2 · price: The weighted average sale price for the transaction reported was $12.0625, and the range of prices were between $11.83 and $12.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 13, 2024 Filed Dec 14, 2024 00:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 27,272 | $1.44 | $39,271.68 |
DisclosureSEC source: 0001415889-24-029377 · form4-12142024_121217.xml · nonDerivative · entry 3 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2024 Filed Dec 14, 2024 00:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 117,333 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-029377 · form4-12142024_121217.xml · derivative · entry 5 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,047 Underlying: Common Stock · 117,333 shares Expires 2029-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 12, 2024 Filed Dec 14, 2024 00:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 117,333 | $12.27 | $1,439,124.44 |
DisclosureSEC source: 0001415889-24-029377 · form4-12142024_121217.xml · nonDerivative · entry 2 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F1 · price: The weighted average sale price for the transaction reported was $12.2653, and the range of prices were between $11.83 and $12.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 12, 2024 Filed Dec 14, 2024 00:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 117,333 | $0.84 | $98,559.72 |
DisclosureSEC source: 0001415889-24-029377 · form4-12142024_121217.xml · nonDerivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 22:41 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-029162 · form4-12122024_101220.xml · derivative · entry 3 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 22:41 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $13.15 | $657,625.00 |
DisclosureSEC source: 0001415889-24-029162 · form4-12122024_101220.xml · nonDerivative · entry 2 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F1 · price: The weighted average sale price for the transaction reported was $13.1525, and the range of prices were between $12.95 and $13.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 22:41 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 50,000 | $0.84 | $42,000.00 |
DisclosureSEC source: 0001415889-24-029162 · form4-12122024_101220.xml · nonDerivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · derivative · entry 9 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 06, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $14.23 | $711,615.00 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · nonDerivative · entry 6 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F3 · price: The weighted average sale price for the transaction reported was $14.2323, and the range of prices were between $14.00 and $14.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 06, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 50,000 | $0.84 | $42,000.00 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · nonDerivative · entry 5 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,640 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · derivative · entry 8 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 49,640 shares Expires 2029-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 05, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 49,640 | $14.13 | $701,641.54 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · nonDerivative · entry 4 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F2 · price: The weighted average sale price for the transaction reported was $14.1346, and the range of prices were between $13.95 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 05, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 49,640 | $0.84 | $41,697.60 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · nonDerivative · entry 3 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · derivative · entry 7 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,640 Underlying: Common Stock · 45,000 shares Expires 2029-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 04, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 45,000 | $13.95 | $627,943.50 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · nonDerivative · entry 2 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F1 · price: The weighted average sale price for the transaction reported was $13.9543, and the range of prices were between $13.77 and $14.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 04, 2024 Filed Dec 7, 2024 00:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 45,000 | $0.84 | $37,800.00 |
DisclosureSEC source: 0001415889-24-028567 · form4-12072024_121247.xml · nonDerivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,740 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-028351 · form4-12042024_091201.xml · derivative · entry 8 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,640 Underlying: Common Stock · 41,740 shares Expires 2029-07-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. F3 · derivative.underlying: Immediately exercisable. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,260 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-028351 · form4-12042024_091201.xml · derivative · entry 7 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,260 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 45,000 | $13.19 | $593,401.50 |
DisclosureSEC source: 0001415889-24-028351 · form4-12042024_091201.xml · nonDerivative · entry 5 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F2 · price: The weighted average sale price for the transaction reported was $13.1867, and the range of prices were between $13.00 and $13.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 41,740 | $0.84 | $35,061.60 |
DisclosureSEC source: 0001415889-24-028351 · form4-12042024_091201.xml · nonDerivative · entry 4 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 3,260 | $0.84 | $2,738.40 |
DisclosureSEC source: 0001415889-24-028351 · form4-12042024_091201.xml · nonDerivative · entry 3 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-028351 · form4-12042024_091201.xml · derivative · entry 6 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,260 Underlying: Common Stock · 45,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 45,000 | $13.67 | $615,217.50 |
DisclosureSEC source: 0001415889-24-028351 · form4-12042024_091201.xml · nonDerivative · entry 2 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 F1 · price: The weighted average sale price for the transaction reported was $13.6715, and the range of prices were between $13.324 and $14.035. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 45,000 | $0.84 | $37,800.00 |
DisclosureSEC source: 0001415889-24-028351 · form4-12042024_091201.xml · nonDerivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2024 Filed Nov 27, 2024 21:11 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 25,000 | $14.39 | $359,750.00 |
DisclosureSEC source: 0001415889-24-027843 · form4-11272024_091151.xml · nonDerivative · entry 3 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,380 Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:11 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 42,186 | $14.05 | $592,569.87 |
DisclosureSEC source: 0001415889-24-027843 · form4-11272024_091151.xml · nonDerivative · entry 2 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,380 F2 · price: The weighted average sale price for the transaction reported was $14.0466, and the range of prices were between $13.95 and $14.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:11 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 32,814 | $14.00 | $459,422.25 |
DisclosureSEC source: 0001415889-24-027843 · form4-11272024_091151.xml · nonDerivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,566 F1 · price: The weighted average sale price for the transaction reported was $14.0008, and the range of prices were between $14.00 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:41 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001209191-24-000806 · doc4.xml · derivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 165,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-23-001929 · doc4.xml · derivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 82,733 | Not disclosed Strike: $1.44 | Not disclosed |
DisclosureSEC source: 0001209191-22-056447 · doc4.xml · derivative · entry 5 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,733 Underlying: Common Stock · 82,733 shares Expires 2031-12-14 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F6 · price: Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 48,260 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001209191-22-056447 · doc4.xml · derivative · entry 4 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,260 Underlying: Common Stock · 48,260 shares Expires 2029-12-17 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F5 · price: Received in exchange for a stock option to acquire 40,833 shares of common stock of ARS with the exercise price of $0.99 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 236,380 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001209191-22-056447 · doc4.xml · derivative · entry 3 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,380 Underlying: Common Stock · 236,380 shares Expires 2029-07-05 F3 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS under the Merger Agreement. F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 236,380 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001209191-22-056447 · doc4.xml · derivative · entry 2 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,380 Underlying: Common Stock · 236,380 shares Expires 2029-07-05 F3 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS under the Merger Agreement. F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantCommon Stock | 236,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-056447 · doc4.xml · nonDerivative · entry 1 Chakma Justin · CIK 0001951238 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,380 F1 · price: Received in exchange for 200,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.